Ooi C.J.Hilmi I.Banerjee R.Chuah S.W.Ng S.C.SHU-CHEN WEIMakharia G.K.Pisespongsa P.Chen M.H.Ran Z.H.Ye B.D.Park D.I.Ling K.L.Ong D.Ahuja V.Goh K.L.Sollano J.Lim W.C.Leung W.K.Ali R.A.R.Wu D.C.Ong E.Mustaffa N.Limsrivilai J.Hisamatsu T.Yang S.K.Ouyang Q.Geary R.De Silva J.H.Rerknimitr R.Simadibrata M.Abdullah M.Leong R.W.L.on behalf of the Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel DiseaseAsian Organization for Crohn'sColitis2021-06-152021-06-1520190815-9319https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068412382&doi=10.1111%2fjgh.14648&partnerID=40&md5=8e176228fe0fa470563a796075588273https://scholars.lib.ntu.edu.tw/handle/123456789/565653The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge. ? 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltdadalimumab; biosimilar; Crohn's disease; inflammatory bowel disease; infliximab; ulcerative colitis[SDGs]SDG3adalimumab; antivirus agent; azathioprine; biological product; biosimilar agent; C reactive protein; calgranulin; corticosteroid; cyclosporine; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; immunomodulating agent; mercaptopurine; tumor necrosis factor inhibitor; biological product; immunologic factor; Asia; capsule endoscopy; clinical practice; comorbidity; Crohn disease; disease activity; hepatitis B; human; irritable colon; pharmacogenetics; practice guideline; priority journal; Review; treatment response; tuberculosis; ulcerative colitis; benchmarking; clinical decision making; consensus; consensus development; Crohn disease; Delphi study; immunology; patient selection; risk factor; treatment outcome; ulcerative colitis; Asia; Benchmarking; Biological Products; Clinical Decision-Making; Colitis, Ulcerative; Consensus; Crohn Disease; Delphi Technique; Humans; Immunologic Factors; Patient Selection; Pharmacogenetics; Risk Factors; Treatment Outcomereview10.1111/jgh.14648308488542-s2.0-85068412382